Dermatologic Manifestations of Homocystinuria Clinical Presentation

  • Author: Janette Baloghova, MD, PhD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Oct 11, 2011
 

History

  • Neurologic features
    • An infant with homocystinuria is usually healthy, although thromboembolic complications of the CNS and psychomotor delay may occur during the first year of life.
    • Alehan et al reports a case of a previously healthy girl, age 3 years 9 months, who presented with right-sided hemiparesis and seizures. Ischemic infarction was confirmed through MRI and magnetic resonance angiography. Based on the clinical and laboratory results, a diagnosis of homocystinuria was made. Homocystinuria is an inherited disorder that affects the metabolism of the amino acid methionine. Although homocystinuria is usually associated with ischemic strokes, the sudden onset of stroke as the initial clinical presentation of homocystinuria is very rare in early childhood. Based on this case, however, metabolic screening for hyperhomocystinemia is recommended in any child presenting with a stroke.[16]
    • A developmental delay is noted when patients are aged 2-3 years.
    • Psychiatric symptoms are also described in approximately one half of patients with homocystinuria.
    • Pyramidal symptoms, including muscle weakness due to an insult to the innervation of the pyramidal motor tract neurons, are occasionally observed in areas such as the leg.
    • Homocystinuria should be included in the differential diagnosis of children with acute/subacute neurological changes, particularly in the context of developmental delay.
  • Skeletal and muscular features
    • The characteristic long thin extremities and arachnodactyly may not appear until late in childhood or during adolescence.
    • In contrast, osteoporosis, especially that of the spine, may have already been present for some time.
  • Ophthalmologic features
    • Severe myopia is the first sign of ectopia lentis and may precede lens dislocation by several months to a year or even longer.
    • Once established, ectopia lentis progresses, even when good biochemical control is maintained.
  • Vascular features
    • Thromboembolic events, such as cerebrovascular occlusions or pulmonary emboli, usually do not occur until adulthood but are reported in childhood and infancy.
    • Vascular occlusive disease is an important and serious feature.
  • Other features
    • Homocystinuria produces high concentrations of amino acids that are competitive inhibitors of tyrosinase.
    • Accordingly, homocystinuria is associated with pale and pink skin. Occasionally, patients have malar rashes, fine fragile hair, and livedo reticularis.
Next

Physical

Marfan syndrome is the primary differential diagnosis. Clinical features of homocystinuria, such as ectopia lentis, dolichocephalia, and chest and spinal deformities, are similar to the features found in patients with Marfan syndrome, although the cerebral symptoms, the changes in the hair, and the disorders of mental development are absent in patients with Marfan syndrome. Generalized osteoporosis, arterial and venous thrombosis, and mental retardation, which are features of homocystinuria, do not occur in patients with Marfan syndrome. In addition, homocysteine is not detectable in the urine of patients with Marfan syndrome.

Findings in homocystinuria include the following:

  • Skin findings
    • Buccal skin shows red macules in children, adolescents, and adults, especially those living in warm environments.
    • Large pores are evident on the facial skin.
    • A livedolike pattern of blood vessels and atrophic, small, cigarette paper–like scars may be observed on the arms and hands.
    • Angiomata may develop in some patients.
    • DL-homocysteine inhibits tyrosinase, the major pigment enzyme. Hypopigmentation may be reversible in patients with pyridoxine-responsive homocystinuria.
    • Pigmentary dilution is observed in patients with homocystinuria. Therefore, an increase of local homocysteine may interfere with normal melanogenesis and may play a role in the pathogenesis of vitiligo. Vitamin B-12 and folic acid, levels of which are decreased in persons with vitiligo, are important cofactors in the metabolism of homocysteine. Shaker and El-Tahlawi found out that an elevated homocysteine level was higher in male patients than in female patients and higher in patients with progressive disease.[17] No significant difference in homocysteine levels was found between either untreated vitiligo patients or patients receiving UV therapy. An elevated homocysteine level may be a precipitating factor for vitiligo in predisposed individuals.
    • The hair can have a coarse texture. Hair stained with acridine orange produces orange-red fluorescence, whereas healthy hair produces green fluorescence.
    • Hyperhidrosis, dry skin, and acrocyanosis may be present.
  • Neurologic findings
    • Patients may behave aggressively.
    • Intelligence is slightly diminished, but in approximately one third of patients, intelligence is in the normal range.
    • Patients' mental capabilities have been reported to be higher in conditions that respond to pyridoxine supplementation than others.
    • Homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency may manifest with variable neurologic manifestations. Radiologic features include white matter changes (leukoencephalopathy).[18]
    • Muscular hypotonia is characteristic.
    • Increased homocysteine levels have been detected in persons with neurological disorders such as Alzheimer disease, idiopathic Parkinson disease, Huntington disease, primary dystonia, and neural tube defects.
  • Skeletal and muscular findings
    • Signs of Marfan syndrome, such as thin and long extremities, arachnodactylia, kyphoscoliosis, and deformations of the thorax, may be present.
    • Osteoporosis, genua valga, pectus carinatum (excavatum), and deformed teeth can be present.
    • The homocysteine concentration is an important risk factor for hip fractures in Parkinson disease patients receiving levodopa.[19]
    • Inguinal and umbilical hernias are observed.
    • Muscular hypotonia is characteristic.
    • Spasms may occur.
  • Ophthalmologic findings
    • Ophthalmologic findings are similar to those in patients with Marfan syndrome.
    • Ectopia lentis is an almost universal feature in patients older than 10 years, and it can even be present in newborns.
    • Other findings include myopia, iridopathy, cataracts, secondary glaucoma, and degeneratio (amotio) retinae.
    • Atrophy of the optic nerve, strabismus, nystagmus, or diminished convergence can occur in some patients.
    • Dislocation of the ocular lenses usually occurs in patients aged 4-10 years.
    • Ocular phenotype in patients with cblC is variable.[20] Ocular involvement seems to be correlated with age at onset. Patients with early-onset cblC developed generally progressive retinal disease ranging from subtle retinal nerve fiber layer loss to advanced macular and optic atrophy with bone-spicule pigmentation. Patients with late-onset disease showed no definite evidence of retinal degeneration.
    • Retinal dysfunction in cblC disease may be more common than previously thought and can involve cones only or both rods and cones. Gaillard et al recommend a formal ocular examination with full-field electroretinography in patients with Cblc disease.[21]
  • Vascular findings
    • Vascular changes mainly affect the lower extremities. Fatal arterial and venous thromboses may occur.
    • Hyperhomocysteinemia is an independent risk factor for atherosclerotic heart disease.
    • Patients with homocystinuria resulting from a deficiency of cystathionine beta-synthase have an increased risk of thrombosis when they also have the Leiden mutation for factor V.
    • Homocysteine induces tissue factor procoagulant activity in cultured human endothelial cells.
    • Reduced survival and abnormally rapid turnover of platelets, fibrinogen, and plasminogen have been noted in patients with homocystinuria.
  • Oral and craniofacial findings
    • D’Alessandro et al reports a case of an 11-year-old patient with methylmalonic aciduria and homocystinuria, which developed during the neonatal period. The patient showed some facial features previously reported in the literature (high forehead, large floppy, low-set ears, flat philtrum, hypotonia of perioral and masticatory muscles), but no dolichocephalic skull nor long face. The patient also showed signs that had not been previously described: epicanthal folds, broad nasal bridge, long and flat philtrum, amimic expression and, particularly, a postural alteration (the head is rotated and bent towards the left shoulder, which is lower than the right one). Such alteration can be attributed to visual impairment and is responsible for breaking muscular and skeletal balance in the frontal plane, thus causing the horizontal planes of both maxillary bones to converge towards the right.[22]
  • Other findings
    • A slightly foul odor of the urine is typical.
    • Spontaneous pneumothorax is reported in some adolescents with homocystinuria.
    • Pancreatitis is described as a complication of homocystinuria.
    • Increased homocysteine levels are implicated in a variety of other clinical conditions, including neural tube defects, spontaneous abortion, placental abruption, renal failure, diabetic microangiopathy, and premenstrual syndrome.
    • Children with autism might have lower baseline plasma concentrations of methionine, SAM, homocysteine, cystathionine, cysteine, and total glutathione and significantly higher concentrations of S-adenosylhomocysteine (SAH), adenosine, and oxidized glutathione. This metabolic profile is consistent with impaired capacity for methylation (significantly lower ratio of SAM to SAH) and increased oxidative stress (significantly lower redox ratio of reduced glutathione to oxidized glutathione) in children with autism. An increased vulnerability to oxidative stress and a decreased capacity for methylation may contribute to the development and clinical manifestation of autism.[23]
    • Cystathionine beta-synthase is encoded on chromosome 21, and deficiency in its activity causes homocystinuria. The most common genetic cause of mental retardation is trisomy 21 or Down syndrome. The levels of cystathionine beta-synthase in the brains of persons with Down syndrome are approximately 3 times greater than those in healthy individuals.[24] The over-expression of cystathionine beta-synthase may cause the developmental abnormality in cognition in Down syndrome children and that may lead to Alzheimer-type disease in Down syndrome adults.
    • Vascular disease is associated with increased plasma asymmetric dimethylarginine and homocysteine, and levels of both are increased in persons with renal failure. The relationship between hyperhomocysteinemia and increased plasma asymmetric dimethylarginine may not be direct, but could be secondary do reduced renal function.[25]
    • Snyderman reports a case of a homocystinuric patient with development of paraparesis and increasing liver failure.[26] A liver transplantation was successful in achieving metabolic control without the need for any dietary restrictions.
    • The latest is a case report of an adult homocystinuric patient, a 47-year-old man, with nontraumatic spontaneous small bowel perforation. It could be hypothesized that connective-tissue weakness in homocystinuria is a result of homocysteine interference with recombinant human fibrillin-1 fragments or cross-linking of collagen through permanent degradation of disulfide bridges and lysine amino acid residues in proteins. DNA analysis showed 3 detectable mutations in the cystathionine beta-synthetase gene, 1278T:c.833T>C, and 2 new mutations, V372G:c.ll33T>G, and D520G:c.l558A>G in the alternatively spliced exon 15.[27]
Previous
Next

Causes

See Pathophysiology.

Previous
 
 
Contributor Information and Disclosures
Author

Janette Baloghova, MD, PhD  Lecturer, Medical Faculty, University of PJ Safarik; Dermatovenerologist, Faculty Hospital of L Pasteur, Slovak Republic

Disclosure: Nothing to disclose.

Coauthor(s)

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Zuzana Baranova, MD, PhD  Senior Lecturer, Department of Dermatology, University of PJ Safarik at Kosice, Slovak Republic

Disclosure: Nothing to disclose.

Specialty Editor Board

Jacek C Szepietowski, MD, PhD  Professor, Vice-Head, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University; Director of the Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Poland

Disclosure: Stiefel GSK Company Salary Employment; Orfagen Consulting fee Consulting; Maruho Consulting fee Consulting; Astellas Consulting fee Consulting; Abbott Consulting fee Consulting; Leo Pharma Consulting fee Consulting

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Warren R Heymann, MD  Head, Division of Dermatology, Professor, Department of Internal Medicine, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Warren R Heymann, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References
  1. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. Jan 1985;37(1):1-31. [Medline].

  2. Finkelstein JD. Inborn errors of sulfur-containing amino acid metabolism. J Nutr. Jun 2006;136(6 Suppl):1750S-1754S. [Medline].

  3. Vyletal P, Sokolova J, Cooper DN, et al. Diversity of cystathionine beta-synthase haplotypes bearing the most common homocystinuria mutation c.833T>C: a possible role for gene conversion. Hum Mutat. Mar 2007;28(3):255-64. [Medline].

  4. Augoustides-Savvopoulou P, Luka Z, Karyda S, et al. Glycine N -methyltransferase deficiency: a new patient with a novel mutation. J Inherit Metab Dis. 2003;26(8):745-59. [Medline].

  5. Orendae M, Pronicka E, Kubalska J, et al. Identification and functional analysis of two novel mutations in the CBS gene in Polish patients with homocystinuria. Hum Mutat. Jun 2004;23(6):631. [Medline].

  6. Whiteman P, Hutchinson S, Handford PA. Fibrillin-1 misfolding and disease. Antioxid Redox Signal. Mar-Apr 2006;8(3-4):338-46. [Medline].

  7. Morel CF, Lerner-Ellis JP, Rosenblatt DS. Combined methylmalonic aciduria and homocystinuria (cblC): phenotype-genotype correlations and ethnic-specific observations. Mol Genet Metab. Aug 2006;88(4):315-21. [Medline].

  8. Baumgartner ER, Wick H, Maurer R, et al. Congenital defect in intracellular cobalamin metabolism resulting in homocysteinuria and methylmalonic aciduria. I. Case report and histopathology. Helv Paediatr Acta. 1979;34(5):465-82. [Medline].

  9. Zavadakova P, Fowler B, Zeman J, et al. CblE type of homocystinuria due to methionine synthase reductase deficiency: clinical and molecular studies and prenatal diagnosis in two families. J Inherit Metab Dis. Oct 2002;25(6):461-76. [Medline].

  10. Coelho D, Suormala T, Stucki M, et al. Gene identification for the cblD defect of vitamin B12 metabolism. N Engl J Med. Apr 3 2008;358(14):1454-64. [Medline].

  11. Elshorbagy AK, Nurk E, Gjesdal CG, et al. Homocysteine, cysteine, and body composition in the Hordaland Homocysteine Study: does cysteine link amino acid and lipid metabolism?. Am J Clin Nutr. Sep 2008;88(3):738-46. [Medline].

  12. Rummel T, Suormala T, Haberle J, et al. Intermediate hyperhomocysteinaemia and compound heterozygosity for the common variant c.677C>T and a MTHFR gene mutation. J Inherit Metab Dis. Jun 2007;30(3):401. [Medline].

  13. Bishop L, Kanoff R, Charnas L, Krenzel C, Berry SA, Schimmenti LA. Severe methylenetetrahydrofolate reductase (MTHFR) deficiency: a case report of nonclassical homocystinuria. J Child Neurol. Jul 2008;23(7):823-8. [Medline].

  14. Jakubowski H, Boers GH, Strauss KA. Mutations in cystathionine beta-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans. FASEB J. Dec 2008;22(12):4071-6. [Medline].

  15. Miroslav Janošík, Jitka Sokolová, Bohumila Janošíková, Jakub Krijt, Veronika Klatovská, Viktor Kožich. Birth Prevalence of Homocystinuria in Central Europe: Frequency and Pathogenicity of Mutation c.1105C>T (p.R369C) in the Cystathionine Beta-Synthase Gene. J Pediatr. March 2009;154(3):431–437.

  16. Alehan F, Saygi S, Gedik S, Kayahan Ulu EM. Stroke in early childhood due to homocystinuria. Pediatr Neurol. Oct 2010;43(4):294-6. [Medline].

  17. Shaker OG, El-Tahlawi SM. Is there a relationship between homocysteine and vitiligo? A pilot study. Br J Dermatol. Sep 2008;159(3):720-4. [Medline].

  18. Tallur KK, Johnson DA, Kirk JM, et al. Folate-induced reversal of leukoencephalopathy and intellectual decline in methylene-tetrahydrofolate reductase deficiency: variable response in siblings. Dev Med Child Neurol. Jan 2005;47(1):53-6. [Medline].

  19. Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med. Nov 2005;118(11):1250-5. [Medline].

  20. Gerth C, Morel CF, Feigenbaum A, Levin AV. Ocular phenotype in patients with methylmalonic aciduria and homocystinuria, cobalamin C type. J AAPOS. Dec 2008;12(6):591-6. [Medline].

  21. Gaillard MC, Matthieu JM, Borruat FX. Retinal dysfunction in combined methylmalonic aciduria and homocystinuria (Cblc) disease: a spectrum of disorders. Klin Monatsbl Augenheilkd. May 2008;225(5):491-4. [Medline].

  22. D'Alessandro G, Tagariello T, Piana G. Oral and craniofacial findings in a patient with methylmalonic aciduria and homocystinuria: review and a case report. Minerva Stomatol. Mar 2010;59(3):129-37. [Medline].

  23. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. Dec 2004;80(6):1611-7. [Medline].

  24. Ichinohe A, Kanaumi T, Takashima S, Enokido Y, Nagai Y, Kimura H. Cystathionine beta-synthase is enriched in the brains of Down's patients. Biochem Biophys Res Commun. Dec 23 2005;338(3):1547-50. [Medline].

  25. Wilcken DE, Wang J, Sim AS, et al. Asymmetric dimethylarginine in homocystinuria due to cystathionine beta-synthase deficiency: relevance of renal function. J Inherit Metab Dis. Feb 2006;29(1):30-7. [Medline].

  26. Snyderman SE. Liver failure and neurologic disease in a patient with homocystinuria. Mol Genet Metab. Mar 2006;87(3):210-2. [Medline].

  27. Diana Muacevic-Katanec, Tihomir Kekez, Ksenija Fumic, Ivo Baric, Marijan Merkler,Jasminka Jakic-Razumovic, et al. Spontaneous Perforation of the Small Intestine, a Novel Manifestation of Classical Homocystinuria in an Adult with New Cystathionine ß-synthetaseGene Mutations. Coll. Antropol. 2011, Mar;35:181-185. [Medline].

  28. Fowler B, Schutgens RB, Rosenblatt DS, et al. Folate-responsive homocystinuria and megaloblastic anaemia in a female patient with functional methionine synthase deficiency (cblE disease). J Inherit Metab Dis. Nov 1997;20(6):731-41. [Medline].

  29. Febriani AD, Sakamoto A, Ono H, et al. Determination of total homocysteine in dried blood spots using high performance liquid chromatography for homocystinuria newborn screening. Pediatr Int. Feb 2004;46(1):5-9. [Medline].

  30. Refsum H, Fredriksen A, Meyer K, et al. Birth prevalence of homocystinuria. J Pediatr. Jun 2004;144(6):830-2. [Medline].

  31. Navratil T, Petr M, Senholdova Z, et al. Diagnostic significance of urinary thiodiglycolic acid as a possible tool for studying the role of vitamins B12 and folates in the metabolism of thiolic substances. Physiol Res. Feb 23 2006;[Medline].

  32. Sen S, Yu J, Yamanishi M, Schellhorn D, Banerjee R. Mapping peptides correlated with transmission of intrasteric inhibition and allosteric activation in human cystathionine beta-synthase. Biochemistry. Nov 1 2005;44(43):14210-6. [Medline].

  33. Jakub Krijt, Jana Kopecká, Aleš Hnízda, Stuart Moat, Leo A. J. Kluijtmans, Philip Mayne, et al. Determination of cystathionine beta-synthase activity in human plasma by LC-MS/MS: potential use in diagnosis of CBS deficiency. J Inherit Metab Dis. February 2011;34(1):49–55. [Medline].

  34. Scherer EB, Stefanello FM, Mattos C, Netto CA, Wyse AT. Homocysteine reduces cholinesterase activity in rat and human serum. Int J Dev Neurosci. Jun 2007;25(4):201-5. [Medline].

  35. Debray FG, Boulanger Y, Khiat A, et al. Reduced brain choline in homocystinuria due to remethylation defects. Neurology. Jul 1 2008;71(1):44-9. [Medline].

  36. Longo D, Fariello G, Dionisi-Vici C, et al. MRI and 1H-MRS findings in early-onset cobalamin C/D defect. Neuropediatrics. Dec 2005;36(6):366-72. [Medline].

  37. Gahl WA, Bernardini I, Chen S, et al. The effect of oral betaine on vertebral body bone density in pyridoxine-non-responsive homocystinuria. J Inherit Metab Dis. 1988;11(3):291-8. [Medline].

  38. Lawson-Yuen A, Levy HL. The use of betaine in the treatment of elevated homocysteine. Mol Genet Metab. Jul 2006;88(3):201-7. [Medline].

  39. Singh RH, Kruger WD, Wang L, et al. Cystathionine beta-synthase deficiency: effects of betaine supplementation after methionine restriction in B6-nonresponsive homocystinuria. Genet Med. Mar-Apr 2004;6(2):90-5. [Medline].

  40. Sakamoto A, Sakura N. Limited effectiveness of betaine therapy for cystathionine beta synthase deficiency. Pediatr Int. Jun 2003;45(3):333-8. [Medline].

  41. Yaghmai R, Kashani AH, Geraghty MT, et al. Progressive cerebral edema associated with high methionine levels and betaine therapy in a patient with cystathionine beta-synthase (CBS) deficiency. Am J Med Genet. Feb 15 2002;108(1):57-63. [Medline].

  42. Tada H, Takanashi J, Barkovich AJ, et al. Reversible white matter lesion in methionine adenosyltransferase I/III deficiency. AJNR Am J Neuroradiol. Nov-Dec 2004;25(10):1843-5. [Medline].

  43. Alan L, Miller ND, Gregory S. Methionine and homocysteine metabolism and the nutritional prevention of certain birth defects and complications of pregnancy. Alt Med Rev. 1996;1:220-35.

  44. Confalonieri M, Parigi P, Scartabellati A, et al. Heterozygosity for homocysteinuria: a detectable and reversible risk factor for pulmonary thromboembolism. Monaldi Arch Chest Dis. Apr 1995;50(2):114-5. [Medline].

  45. Cruysberg JR, Boers GH, Trijbels JM, Deutman AF. Delay in diagnosis of homocystinuria: retrospective study of consecutive patients. BMJ. Oct 26 1996;313(7064):1037-40. [Medline].

  46. Kim SZ, Santamaria E, Jeong TE, et al. Methionine adenosyltransferase I/III deficiency: two Korean compound heterozygous siblings with a novel mutation. J Inherit Metab Dis. Dec 2002;25(8):661-71. [Medline].

  47. Kozich Viktor, Sokolova Jitka, Klatovska Veronika, Krijt Jakub, Janosik Miroslav, Jelinek Karel, et al. Cystathionine b-Synthase Mutations: Effect of Mutation Topology on Folding and Activity. HUMAN MUTATION. 2010, No. 7;Vol. 31:809–819.

  48. Kraus JP. Komrower Lecture. Molecular basis of phenotype expression in homocystinuria. J Inherit Metab Dis. 1994;17(4):383-90. [Medline].

  49. Moat SJ, Bao L, Fowler B, et al. The molecular basis of cystathionine beta-synthase (CBS) deficiency in UK and US patients with homocystinuria. Hum Mutat. Feb 2004;23(2):206. [Medline].

  50. Nugent A, Hadden DR, Carson NA. Long-term survival of homocystinuria: the first case. Lancet. Aug 22 1998;352(9128):624-5. [Medline].

  51. Orendac M, Zeman J, Stabler SP, et al. Homocystinuria due to cystathionine beta-synthase deficiency: novel biochemical findings and treatment efficacy. J Inherit Metab Dis. 2003;26(8):761-73. [Medline].

  52. Scriver CR, Beaudet AL, Sly WS. The Metabolic and Molecular Bases of Inherited Diseases. 7th ed. New York, NY: McGraw-Hill; 1995.

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.